Unjoni Ewropea - Malti - EMA (European Medicines Agency)

chiesi farmaceutici s.p.a - levofloxacin - cystic fibrosis; respiratory tract infections - antibatteriċi għal użu sistemiku, - quinsair huwa indikat għall-ġestjoni ta kroniku pulmonari infezzjonijiet minħabba pseudomonas aeruginosa f'pazjenti adulti b'fibrożi ċistika. għandha tingħata kunsiderazzjoni għall-gwida uffiċjali dwar l-użu xieraq ta ' sustanzi antibatteriċi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

advanced accelerator applications - lutetium (177lu) oxodotreotide - tumuri newroentokrini - radjufarmaċewtiċi terapewtiċi oħra - lutathera huwa indikat għat-trattament ta ' unresectable jew metastatic, b'mod progressiv, ukoll differenzjati (g1 u g2), somatostatin r-riċevitur gastroenteropancreatic pożittiv neuroendocrine tumuri (gep‑nets) fl-adulti.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

a. menarini industrie farmaceutiche riunite s.r.l. - delafloxacin meglumine - infezzjonijiet akkwistati mill-komunità - antibatteriċi għal użu sistemiku, - quofenix is indicated for the treatment of the following infections in adults:acute bacterial skin and skin structure infections (absssi),community-acquired pneumonia (cap), when it is considered inappropriate to use other antibacterial agents that are commonly recommended for the initial treatment of these infections (see sections 4. 4 u 5. għandha tingħata kunsiderazzjoni għall-gwida uffiċjali dwar l-użu xieraq ta ' sustanzi antibatteriċi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - aġenti antineoplastiċi - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited - brinzolamide, timolol maleate - glaucoma, open-angle; ocular hypertension - oftalmoloġiċi - tnaqqis fil-pressjoni intraokulari (iop) f'pazjenti adulti bi glawkoma b'angolu miftuħ jew pressjoni għolja fl-għajnejn li għalihom il-monoterapija tipprovdi tnaqqis iop insuffiċjenti.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

viatris healthcare limited - fenofibrate, simvastatin - dyslipidemias - aġenti li jimmodifikaw il-lipidi - cholib huwa indikat bħala terapija adjunctive tad-dieta u jeżerċita fir-riskju għoli kardjovaskulari pazjenti adulti ma dyslipidaemia imħallat li tnaqqas it-trigliċeridi u jżidu l-livelli hdl c meta livelli ldl c huma kkontrollati b'mod adegwat bl-doża korrispondenti ta ' l- simvastatin monotherapy.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

teva b.v. - colistimethate sodium - fibrożi ċistika - antibatteriċi għal użu sistemiku, - colobreathe huwa indikat għall-immaniġġjar ta 'infezzjonijiet kroniċi pulmonari minħabba pseudomonas aeruginosa f'pazjenti b'fibrożi ċistika (cf) ta' sitt snin u aktar. għandha tingħata kunsiderazzjoni għall-gwida uffiċjali dwar l-użu xieraq ta ' sustanzi antibatteriċi.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

novartis europharm limited - travoprost, timolol - glaucoma, open-angle; ocular hypertension - oftalmoloġiċi - it-tnaqqis tal-pressjoni intraocular (iop) fil-pazjenti adulti ma miftuħ-angolu glaucoma jew ipertensjoni okulari li huma responsivi biżżejjed biex beta-blockers topika jew analogi prostaglandin.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pharmaand gmbh - darifenacin hydrobromide - urinary incontinence, urge; urinary bladder, overactive - urologicals, mediċini għall fil-frekwenza urinarja u l-inkontinenza ta ' l - - trattament sintomatiku ta 'inkontinenza u / jew żieda fil-frekwenza ta' l-awrina u l-urġenza li jistgħu jseħħu f'pazjenti adulti b'sindrome tal-bużżieqa ta '.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

dompé biotec s.p.a. - darbepoetin alfa - kidney failure, chronic; anemia; cancer - preparazzjonijiet antianemiċi - kura ta 'anemija sintomatika assoċjata ma' insuffiċjenza renali kronika (crf) f'adulti u pazjenti pedjatriċi. kura ta ' anemija sintomatika f'pazjenti adulti bil-kanċer tumuri malinni mhux majelojdi li qed jirċievu l-kimoterapija.